Research programme: checkpoint kinase 1 inhibitors - Cascadian/Sentinel

Drug Profile

Research programme: checkpoint kinase 1 inhibitors - Cascadian/Sentinel

Alternative Names: CASC-578; S024; S070; S081; S091; S158; S209

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Sentinel Oncology
  • Developer Cascadian Therapeutics; Sentinel Oncology
  • Class Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors; DNA repair inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Pharmacokinetics data from a preclinical study presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 09 Mar 2017 Cascadian Therapeutics receives patent allowance for compounds and compositions of Checkpoint kinase 1 inhibitors in USA (Cascadian Therapeutics Form 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top